The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy
- 31 March 2005
- journal article
- review article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 80 (3) , 379-388
- https://doi.org/10.4065/80.3.379
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention TrialJournal of Bone and Mineral Research, 2004
- Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosisCurrent Medical Research and Opinion, 2004
- Bone quality: where do we go from here?Osteoporosis International, 2003
- Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With RisedronateJournal of Bone and Mineral Research, 2003
- IX: Summary of Meta-Analyses of Therapies for Postmenopausal OsteoporosisEndocrine Reviews, 2002
- Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal OsteoporosisOsteoporosis International, 2001
- Bisphosphonates in osteoporosis: recent clinical experienceExpert Opinion on Pharmacotherapy, 2000
- Practical Clinical Application of Biochemical Markers of Bone TurnoverJournal of Clinical Densitometry, 1999
- Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective studyJournal of Bone and Mineral Research, 1996
- Use of bisphosphonates in the prevention of bone loss and fracturesThe American Journal of Medicine, 1991